Skip to main content
SpringerLink
Log in

Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin

Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

An antiemetic regimen for patients taking paclitaxel and carboplatin (TC) includes dexamethasone (20 mg) to protect against hypersensitivity. Chemotherapy-induced nausea and vomiting (CINV), however, is difficult to adequately control in patients receiving TC. In the present study, we retrospectively investigated risk factors for CINV in patients receiving TC with this antiemetic regimen based on a questionnaire.

Methods

Eligible patients were diagnosed with gynecologic cancer and receiving paclitaxel (175 mg/m2) intravenously for 3 h and carboplatin (area under the curve 5 mg/mL per min) on day 1 every 3 weeks in our institution, and treated with granisetron (3 mg) and dexamethasone (20 mg) for antiemesis. Data of nausea and vomiting assessed by Common Terminology Criteria for Adverse Events version4.0 were collected from the medical records. Patients were asked to complete a questionnaire including items such as age and hyperemesis. Logistic regression analysis was used to evaluate univariate and independent multivariate associations with items on nausea of grade 2 or greater and vomiting of grade 1 or greater.

Results

On univariate logistic analysis, no item was significantly associated with nausea of grade 2 or greater. Hypertension and hyperemesis gravidarum and adjuvant chemotherapy were significantly associated with delayed vomiting of grade 1 or greater. Multivariate analysis was performed with delayed vomiting of grade 1 or greater as an endpoint, and the resulting independent items were hypertension and hyperemesis gravidarum.

Conclusions

The present study showed that the risk factor for delayed vomiting of grade 1 or higher was a history of hyperemesis gravidarum in patients receiving conventional TC with dexamethasone (20 mg) and granisetron. Therefore, in patients with this risk factor, criteria of major organizations should be followed first.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ushijima K (2009) Current status of gynecologic cancer in Japan. J Gynecol Oncol 20(2):67–71. doi:10.3802/jgo.2009.20.2.67

    Article  PubMed Central  PubMed  Google Scholar 

  2. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH (1983) On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19(2):203–208

    Article  CAS  PubMed  Google Scholar 

  3. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7(2):189–195

    Article  CAS  PubMed  Google Scholar 

  4. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95(1):155–163. doi:10.1002/cncr.10630

    Article  PubMed  Google Scholar 

  5. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. doi:10.1200/JCO.2010.34.4614

    PubMed Central  Google Scholar 

  6. Gralla RJ, Roila F, Tonato M, Herstedt J (2011) MASCC Antiemetic Guidelines. http://www.mascc.org/antiemetic-guidelines. Accessed 5 Oct 2012

  7. NCCN Clinical Practice Guideline in Oncology (2012) Antiemesis. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed 5 Oct 2012

  8. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8):viii7–viii12. doi:10.1093/annonc/mdi961

    PubMed  Google Scholar 

  9. Miller D, Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, Tewari K, DiSilvestro P, Pearl M, Zaino R (2012) Late-Breaking Abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125(3):771. doi:10.1016/j.ygyno.2012.03.034

    Article  Google Scholar 

  10. Kitagawa R, Katsumata N, Shibata T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H, Kamura T (2012) A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505). J Clin Oncol 30(15_suppl):5006

    Google Scholar 

  11. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320–1329

    Article  PubMed  Google Scholar 

  12. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96(22):1682–1691

    Article  CAS  PubMed  Google Scholar 

  13. Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423–431. doi:10.1007/s00520-009-0680-9

    Article  PubMed  Google Scholar 

  14. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570–1577

    Article  CAS  PubMed  Google Scholar 

  15. Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18(9):1171–1177. doi:10.1007/s00520-009-0737-9

    Article  PubMed  Google Scholar 

  16. Warr DG, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer. doi:10.1007/s00520-010-0899-5

    Google Scholar 

  17. Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64(5):1117–1122

    Article  CAS  PubMed  Google Scholar 

  18. Hesketh PJ, Aapro M, Street JC, Carides AD (2009) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. doi:10.1007/s00520-009-0737-9

    Google Scholar 

  19. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24(27):4472–4478. doi:10.1200/JCO.2006.05.6382

    Article  CAS  PubMed  Google Scholar 

  20. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331–1338

    Article  CAS  PubMed  Google Scholar 

  21. Siddiqui MA, Scott LJ (2004) Palonosetron. Drugs 64(10):1125–1132 (discussion 1133–1124)

    Article  CAS  Google Scholar 

  22. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011–1015. doi:10.1038/sj.bjc.6603048

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Aapro M, Fabi A, Nole F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21(5):1083–1088. doi:10.1093/annonc/mdp584

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan

    Naoto Furukawa, Juria Akasaka, Aiko Shigemitsu, Yoshikazu Sasaki, Akira Nagai, Ryuji Kawaguchi & Hiroshi Kobayashi

Authors
  1. Naoto Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juria Akasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aiko Shigemitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshikazu Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akira Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ryuji Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroshi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoto Furukawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Furukawa, N., Akasaka, J., Shigemitsu, A. et al. Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin. Arch Gynecol Obstet 289, 859–864 (2014). https://doi.org/10.1007/s00404-013-3058-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-3058-7

Keywords

search

Navigation